Alveolar Distraction Osteogenesis: Biological Principles, Indications and Clinical Protocol in Reconstructive Implantology

Alveolar distraction osteogenesis (ADO) applies to maxillary bone tissue the biological principle discovered by Ilizarov in 1950 on the appendicular skeleton: progressive traction on an early-healing osteotomy stimulates bone regeneration in the distraction gap through intramembranous bone formation along tensile force lines. ADO's fundamental biological advantage over conventional bone grafts is simultaneous growth of the overlying soft tissue (mucosa, periosteum, connective tissue, vessels, nerves) during the distraction phase — eliminating the need for additional mucosal augmentation surgery and reducing the risk of graft exposure, the main complication of vertical GBR. Vertical bone augmentation — indicated when residual bone height is insufficient for standard implants (<8 mm in the mandible above the inferior alveolar nerve, <6 mm in the maxilla before the sinus) — is the clinical context where ADO offers the most significant advantages over alternatives.

The distraction protocol is organized into three sequential phases: latency, distraction and consolidation. The latency phase — between the osteotomy and the start of distraction — lasts 5-7 days in healthy adults. This period allows initial callus formation, which will respond to traction with regeneration instead of simple fragment separation. Too short a latency (<5 days) risks producing fibrosis at the distraction center instead of regenerated bone; too long a latency (>10 days) risks partial consolidation that prevents distraction without fracture. The distraction phase — typically 0.5-1 mm/day, divided into 2-4 activations of 0.25 mm — produces a progressive gap between the transported bone segment (bone transport disc) and the bone base. The rate of 1 mm/day is supported by Ilizarov's histological studies documenting optimal intramembranous bone tissue formation; faster rates produce fibrosis, slower rates premature consolidation. The consolidation phase — typically 8-12 weeks — allows mineralization and remodeling of the regenerated bone before implant loading.

Alveolar distractors available for ADO are divided into intraosseous (fully within the bone) and extraosseous (with the distractor body extramucosal). Intraosseous distractors — typically titanium, with an internal screw mechanism activated with a hex key — offer the advantage of a low intraoral profile and less functional disruption during distraction, but have a limited distraction range (typically 8-12 mm) and require surgical removal. Extraosseous distractors — with arms emerging from the mucosa — allow greater distraction distances and the ability to modify the vector direction during treatment, but are bulkier and require dedicated hygiene of the transmucosal emergence pin to prevent peri-pin infections. Choice depends on the amount of augmentation needed, location (anterior vs. posterior area), and surgeon preference.

ADO results in terms of vertical bone gain documented in the literature are consistently favorable: Esposito et al.'s systematic review (Cochrane Database, 2009) reported average gains of 8-10 mm in prospective studies, with stable maintenance during post-implant follow-up (average crestal bone loss 0.2-0.5 mm/year, comparable to implants in native bone). Implant survival rates in ADO-regenerated bone are 92-98% at 3-5 years, with some series reporting values overlapping with non-regenerated native bone. Comparison with vertical GBR for significant vertical bone gain (>5 mm) — summarized in Lai et al.'s meta-analysis, Clin Implant Dent Relat Res, 2019 — shows no significant differences in implant survival rates but documents a lower incidence of site exposure (5-12% for ADO vs. 15-30% for vertical GBR).

ADO's specific complications deserve detailed discussion for properly communicating risk to the patient. Deviation of the distraction vector — with tilting of the transported segment instead of pure vertical movement — occurs in 20-40% of cases, requiring surgical correction or accepting a suboptimal implant position. Fibrous tissue formation instead of bone at the distraction center — linked to excessive rates, poor compliance with activations, or segment fixation problems — is reported in 5-15% of cases. Distractor fracture — a rare event (<2%) but requiring reintervention — is more common in devices from manufacturers with lower metallurgical quality. Neuropraxia of the inferior alveolar nerve in mandibular ADO — from tension during distraction — is reversible in most cases but requires a conservative approach and sensory monitoring during the distraction phase.

Current ADO indications in reconstructive implantology have been redefined as competing techniques have evolved. ADO remains the treatment of choice for vertical deficits greater than 5-6 mm in younger patients (<50 years) where biological bone regeneration is optimal, in cases with a concurrent soft tissue deficit (which ADO simultaneously corrects), and in cases where a previously failed GBR site has reduced residual bone quality. For vertical deficits of 3-5 mm in healthy adult patients, GBR with titanium-reinforced non-resorbable membranes (Ti-mesh) offers comparable results with lower procedural complexity and better patient compliance — since ADO requires daily activations for 2-3 weeks, frequent follow-up visits, and a 2-3 month consolidation phase before implant placement.